Lupus erythematosus - Lúpus Eritematoso
☆ Nos resultados do Stiftung Warentest de 2022 da Alemanha, a satisfação do consumidor com o ModelDerm foi apenas ligeiramente inferior do que com as consultas pagas de telemedicina.
Aparece como um eritema levemente arroxeado.
A erupção cutânea em forma de borboleta que normalmente aparece no rosto.
relevance score : -100.0%
ReferencesIdentificar e classificar o cutaneous lupus erythematosus (CLE) apresenta desafios diagnósticos, pois deve ser distinguido do systemic lupus erythematosus com envolvimento cutâneo. Estudos recentes esclarecem os fatores genéticos, ambientais e imunológicos subjacentes ao CLE. Em particular, a indução por drogas surgiu como um dos gatilhos mais importantes para o CLE. O tratamento inclui terapias tópicas e sistêmicas, entre elas produtos biológicos promissores como belimumab, rituximab, ustekinumab, anifrolumab e BIIB059, com eficácia demonstrada em ensaios clínicos.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) abrange vários problemas de pele, alguns dos quais podem estar associados a condições de saúde mais amplas. É categorizado em diferentes tipos, como acute CLE (ACLE), sub‑acute CLE (SCLE) e chronic CLE (CCLE). O CCLE inclui discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus e lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus eritematoso é um grupo de doenças autoimunes que podem afetar diferentes partes do corpo. Alguns tipos, como systemic lupus erythematosus (SLE), afetam vários órgãos, enquanto outros, como cutaneous lupus erythematosus (CLE), afetam principalmente a pele. Classificamos os diferentes tipos de CLE com base em uma combinação de sinais clínicos, exames histológicos e exames laboratoriais, embora haja grande variação entre os indivíduos. As lesões cutâneas geralmente surgem em decorrência de fatores como exposição solar, tabagismo ou uso de certos medicamentos.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
A causa do lúpus eritematoso (lupus erythematosus) não é clara. Em gêmeos idênticos, se um for afetado, há 24 % de chance de que o outro também seja afetado. Acredita‑se que hormônios sexuais femininos, exposição solar, tabagismo, deficiência de vitamina D e algumas infecções aumentem o risco.
Os tratamentos podem incluir AINEs, corticosteróides, imunossupressores, hidroxicloroquina e metotrexato. Embora eficazes, os corticosteróides podem causar efeitos colaterais quando usados a longo prazo.